about
Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation and ERK1/2 and p38 MAPK activation.CDG Therapies: From Bench to Bedside.Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping reviewInternational clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow upKeeping an eye on congenital disorders of O-glycosylation: A systematic literature reviewArtificial Intelligence (AI) in Rare Diseases: Is the Future Brighter?CDG and immune response: From bedside to bench and backThe challenge of CDG diagnosis
P50
Q47272986-869E57A7-8DF0-4296-A61E-2B2C75DB947CQ52558429-6E330B08-4767-48A0-BE04-21991836F703Q59806220-32ED7D78-7FD8-46E2-8351-88469407689DQ64040674-73574534-FB59-40F2-9C0F-6D6C5F8932B5Q91444615-1B464B1C-294F-4C94-8031-D982E90772D6Q91552389-C4A27ABF-87CF-4B3D-B239-FE2682D9628DQ92076217-4B963C18-B8C4-4945-981A-1353F59F143CQ93219190-D9E8972E-C5AC-4802-8E07-6EFD8E95176D
P50
description
researcher (ORCID 0000-0001-5049-0579)
@en
name
Carlota Pascoal
@en
type
label
Carlota Pascoal
@en
prefLabel
Carlota Pascoal
@en
P31
P496
0000-0001-5049-0579